Osteoarthritis — an untreatable disease?
The DOI matches its Crossref record; 123 of the 124 references it cites were found in a registry or an index.
Abstract
Osteoarthritis is a painful and disabling disease that affects millions of patients. Its aetiology is largely unknown, but is most likely multi-factorial. Osteoarthritis poses a dilemma: it often begins attacking different joint tissues long before middle age, but cannot be diagnosed until it becomes symptomatic decades later, at which point structural alterations are already quite advanced. In this review, osteoarthritis is considered as a disease of the whole joint that may result from multiple pathophysiological mechanisms, one of which is the dysregulation of lipid homeostasis. No proven disease-modifying therapy exists for osteoarthritis and current treatment options for chronic osteoarthritic pain are insufficient, but new pharmacotherapeutic options are emerging.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a chronic disease characterized by degeneration of articular cartilage leading to pain and physical disability.”
From Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment (2017) · cites this paper as [10]
In the citing paper
“Aging and trauma are risk factors for the development of osteoarthritis (OA)10”
From Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment (2017) · cites this paper as [10]
Citations
Cites
1 retracted
Yagami, K., Uyama, Y., Yoshizawa, Y., Kakuta, S., Yamaguchi, A., & NAGUMO, M. (2004) · Bone · doi:10.1016/j.bone.2003.12.016 · Cited by 17 · cited 1×
“Interestingly, adipocytes share a common mesenchymal stem-cell precursor with osteoblasts and chondrocyte”
BackgroundRetractedCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734 · cited 1×
“COX1 is constitutively expressed in many cell types, whereas COX2 is induced at the site of inflammation, although it is also constitutively expressed in the kidney, for exampl”
BackgroundLeptin Inhibits Bone Formation through a Hypothalamic Relay
Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, F. T., Shen, J., Vinson, C., Rueger, J. M., & Karsenty, G. (2000) · Cell · doi:10.1016/s0092-8674(00)81558-5 · Cited by 2,077
Jordan, K. M., Arden, N. K., Doherty, M., Bannwarth, B., Bijlsma, J. W. J., Dieppe, P., Gunther, K., Hauselmann, H., Herrero-Beaumont, G., Kaklamanis, P., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011742 · Cited by 2,048 · cited 1×
“It is recommended as a first-line oral analgesic for knee O”
BackgroundCharbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Leptin Regulates Bone Formation via the Sympathetic Nervous System
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., Armstrong, D., Ducy, P., & Karsenty, G. (2002) · Cell · doi:10.1016/s0092-8674(02)01049-8 · Cited by 1,735 · cited 1×
“Besides its role in regulating caloric intake, leptin regulates bone mass and mineralization through a neuroendocrine pathway involving the sympathetic nervous syste”
BackgroundWarner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Ahima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Samad, T. A., Moore, K. A., Sapirstein, A., Billet, S., Allchorne, A., Poole, S., Bonventre, J. V., & Woolf, C. J. (2001) · Nature · doi:10.1038/35068566 · Cited by 1,281
Quadriceps Weakness and Osteoarthritis of the Knee
Slemenda, C., Brandt, K. D., Heilman, D. K., Mazzuca, S., Braunstein, E. M., Katz, B. P., & Wolinsky, F. D. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-2-199707150-00001 · Cited by 966 · cited 2×
“Slemenda et al.95 examined the association between quadriceps strength, OA and knee pain.”
BackgroundArticular cartilage and changes in Arthritis: Cell biology of osteoarthritis
Sandell, L. J., & Aigner, T. (2001) · Arthritis Research & Therapy · doi:10.1186/ar148 · Cited by 907 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=3479">IGF1 ) and bone morphogenetic proteins (BMPs) are endogenous anabolic factors that stimulate cartilage generation and remodellin”
BackgroundMcAlindon, T. E., LaValley, M. P., Gulin, J. P., & Felson, D. T. (2000) · JAMA · doi:10.1001/jama.283.11.1469 · Cited by 849 · cited 1×
“Although their long-term use seems to be safe, their efficacy remains controversia”
BackgroundHannan, M. T., Felson, D. T., & Pincus, T. (2000) · PubMed · Cited by 720
Osteoarthritis, angiogenesis and inflammation
Bonnet, C. S. (2005) · Rheumatology · doi:10.1093/rheumatology/keh344 · Cited by 709 · cited 1×
“In addition, endochondral ossification occurs alongside angiogenesi”
Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16893-1 · Cited by 701
Woolf, C. J., Allchorne, A., Safieh‐Garabedian, B., & Poole, S. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701148 · Cited by 675 · cited 1×
“IL-1β and TNFα have also been shown to contribute in vivo to behavioural signs of inflammatory hyperalgesi”
BackgroundSystems biology in drug discovery
Butcher, E. C., Berg, E. L., & Kunkel, E. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1017 · Cited by 605 · cited 1×
“has proposed that, among other strategies, a systems biology approach could be taken to avoid further delays in the development of new medical entities reaching patients — an approach that is expected to address many biological problems in drug discover”
BackgroundIntra-articular Hyaluronic Acid in Treatment of Knee Osteoarthritis: A Meta-analysis
Lo, G. H., LaValley, M., McAlindon, T., & Felson, D. T. (2003) · JAMA · doi:10.1001/jama.290.23.3115 · Cited by 602 · cited 1×
“There is only a small effect in the treatment of knee OA compared with placebo injectio”
BackgroundFailing the Public Health — Rofecoxib, Merck, and the FDA
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048286 · Cited by 599
Safieh‐Garabedian, B., Poole, S., Allchorne, A., Winter, J., & Woolf, C. J. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15035.x · Cited by 595
The burden of musculoskeletal conditions at the start of the new millennium.
(2003) · PubMed · Cited by 595
Mechanisms of inflammatory pain
Kidd, B. L., & Urban, L. A. (2001) · British Journal of Anaesthesia · doi:10.1093/bja/87.1.3 · Cited by 590 · cited 1×
“This enhanced nociceptive input in turn leads to altered processing in the spinal cord and higher centres (central sensitization), which results in a multiple amplification of pain sensatio”
BackgroundEvidence for a key role of leptin in osteoarthritis
Dumond, H., Presle, N., Terlain, B., Mainard, D., Loeuille, D., Netter, P., & Pottie, P. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11303 · Cited by 564 · cited 1×
“LEPTIN and its receptor have been identified in human cartilage and display stimulatory effects on proteoglycan synthesis in rat”
BackgroundHayami, T., Pickarski, M., Wesolowski, G. A., Mclane, J., Bone, A., Destefano, J., Rodan, G. A., & Duong, L. T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20124 · Cited by 560 · cited 1×
“Although alendronate and risedronate showed some evidence of joint protection in experimental OA in rats and rabbit”
BackgroundSensorimotor changes and functional performance in patients with knee osteoarthritis
Hurley, M. V., Scott, D. L., Rees, J., & Newham, D. J. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.11.641 · Cited by 559 · cited 1×
“Many patients with knee OA experience atrophy of muscles surrounding the involved joint, in particular the quadriceps muscle ( Figs 2 , 4”
BackgroundAn update on the pathogenesis and epidemiology of osteoarthritis
Felson, D. T. (2004) · Radiologic Clinics of North America · doi:10.1016/s0033-8389(03)00161-1 · Cited by 557 · cited 1×
“This risk factor must include more than just mechanical load, otherwise it would be difficult to explain why obesity increases the risk not only of knee OA, but also of hip and hand O”
BackgroundRisk factors for osteoarthritis: genetics
Spector, T. D., & MacGregor, A. J. (2004) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2003.09.005 · Cited by 519
Mechanisms of Pain in Arthritis
SCHAIBLE, H., EBERSBERGER, A., & VON BANCHET, G. S. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04234.x · Cited by 514
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Expression profiling of metalloproteinases and their inhibitors in cartilage
Kevorkian, L., Young, D. A., Darrah, C., Donell, S. T., Shepstone, L., Porter, S., Brockbank, S. M. V., Edwards, D. R., Parker, A. E., & Clark, I. M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11433 · Cited by 404 · cited 1×
“They are differentially induced in human osteoarthritic tissue and human synovial fibroblast”
BackgroundGarnero, P., Ayral, X., Rousseau, J., Christgau, S., Sandell, L. J., Dougados, M., & Delmas, P. D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10576 · Cited by 398 · cited 1×
“These also include the type II collagen crosslinking C-telopeptide region fragments (CTX-II”
BackgroundOprée, A., & Kress, M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06289.2000 · Cited by 359 · cited 1×
“IL-1β and TNFα have the capacity to excite and also to sensitize nociceptor”
BackgroundCerejo, R., Dunlop, D. D., Cahue, S., Channin, D., Song, J., & Sharma, L. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10530 · Cited by 355
Bensen, W. G., Fiechtner, J. J., McMillen, J. I., Zhao, W. W., Yu, S. S., Woods, E. M., Hubbard, R. C., Isakson, P. C., Verburg, K. M., & Geis, G. S. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.11.1095 · Cited by 348 · cited 1×
“In fact, in terms of analgesic efficacy and improvement of function in OA patients, selective COX2 inhibitors do indeed seem to be as good as comparable NSAID”
BackgroundLin, J., Zhang, W., Jones, A., & Doherty, M. (2004) · BMJ · doi:10.1136/bmj.38159.639028.7c · Cited by 337 · cited 1×
“Topical NSAIDs are superior to placebo in reducing knee OA pain for 2 weeks, but not when given over a period of 3–4 week”
BackgroundCyclooxygenase-2 and prostaglandins in articular tissues
Martel-Pelletier, J., Pelletier, J.-P., & Fahmi, H. (2003) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(03)00134-3 · Cited by 333
Quadriceps Strength and Osteoarthritis Progression in Malaligned and Lax Knees
Sharma, L., Dunlop, D. D., Cahue, S., Song, J., & Hayes, K. W. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00006 · Cited by 321 · cited 1×
“However, in OA patients with mis-aligned and lax knees, greater quadriceps strength was associated with increased likelihood of OA progressio”
BackgroundZhang, W., Jones, A., & Doherty, M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018531 · Cited by 321 · cited 1×
“Recent meta-analyses of available clinical studies, however, reveal that acetaminophen is less effective than NSAIDs and COX2 inhibitor”
BackgroundSubchondral bone in osteoarthritis
Grynpas, M. D., Alpert, B., Katz, I., Lieberman, I., & Pritzker, K. P. H. (1991) · Calcified Tissue International · doi:10.1007/bf02555898 · Cited by 294
Transchondral Fractures (Osteochondritis Dissecans) of the Talus
Berndt, A. L., & Harty, M. (2004) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200406000-00031 · Cited by 289
Lohmander, L. S., Dalén, N., Englund, G., Hämäläinen, M., Jensen, E. M., Karlsson, K., Odensten, M., Ryd, L., Sernbo, I., Suomalainen, O., et al. (1996) · Annals of the Rheumatic Diseases · doi:10.1136/ard.55.7.424 · Cited by 277
Subchondral bone changes in hand and knee osteoarthritis detected by radiography
Buckland-Wright, C. (2004) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2003.09.007 · Cited by 270 · cited 1×
“The cortical subchondral plate thickens, and the trabecular bone becomes increasingly irregula”
BackgroundNIH Consensus Statement on Total Knee Replacement December 8-10, 2003*
(2004) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200406000-00030 · Cited by 269
Day, R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.12.1781 · Cited by 264
Lohmander, L. S., Atley, L. M., Pietka, T. A., & Eyre, D. R. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11326 · Cited by 263 · cited 2×
“Lohmander et al.46 reported an increase in the numbers of fragments of collagen type II soon after injury and arthritis.”
BackgroundTopical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis
Mason, L., Moore, R. A., Edwards, J. E., Derry, S., & McQuay, H. J. (2004) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-5-28 · Cited by 243 · cited 1×
“Topical salicylates and capsaicin have been used in a small number of trials and demonstrated a lower efficacy than topical NSAID”
BackgroundRonesi, J., Gerdeman, G. L., & Lovinger, D. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5214-03.2004 · Cited by 228
Osteoarthritis: Is it a disease of cartilage or of bone?
Felson, D. T., & Neogi, T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20051 · Cited by 223 · cited 1×
“This question is difficult to answer in human patients because OA is usually only manifest in advanced symptomatic stages of the disease, but there is evidence from longitudinal animal studies of OA that cartilage destruction might in fact precede bone patholog”
BackgroundRudolphi, K., Gerwin, N., Verzijl, N., van der Kraan, P., & van den Berg, W. (2003) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(03)00153-5 · Cited by 213 · cited 1×
“The pathophysiological importance of IL-1β has been elucidated by both pralnacasan (Vertex/Sanofi-Aventis), an ICE inhibitor that reduced joint damage in two murine models of O”
BackgroundSelf-citationSkiles, J. W., Gonnella, N. C., & Jeng, A. Y. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364018 · Cited by 209
LeGrand, A., Fermor, B., Fink, C., Pisetsky, D. S., Weinberg, J. B., Vail, T. P., & Guilak, F. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<1998::aid-art348>3.0.co;2-t · Cited by 204
Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism
Aspden, R. M., Scheven, B. A., & Hutchison, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04264-1 · Cited by 196 · cited 1×
“This pattern of joint involvement points to the hypothesis that joint damage might be caused by a multitude of systemic factors, including metabolic triggers such as lepti”
BackgroundLanyon, P., O'Reilly, S., Jones, A., & Doherty, M. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.10.595 · Cited by 195 · cited 1×
“and that osteophyte formation in the human knee joint is closely associated with, and is indeed more accurately predictive of, pain than the rate of joint-space narrowin”
BackgroundToda, Y., Toda, T., Takemura, S., Wada, T., Morimoto, T., & Ogawa, R. (1998) · PubMed · Cited by 184
Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031.
Badley, E. M., & Wang, P. (1998) · PubMed · Cited by 179
Human Articular Chondrocytes Express Functional Leptin Receptors
Figenschau, Y., Knutsen, G., Shahazeydi, S., Johansen, O., & Sveinbjörnsson, B. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5543 · Cited by 169 · cited 1×
“LEPTIN and its receptor have been identified in human cartilage and display stimulatory effects on proteoglycan synthesis in rat”
BackgroundPain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic.
Creamer, P., Hunt, M., & Dieppe, P. A. (1996) · PubMed · Cited by 167
Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis
Lindblad, S., & Hedfors, E. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301001 · Cited by 166 · cited 1×
“Synovial inflammation is often confined to areas of the synovial membrane close to the cartilag”
BackgroundTegeder, I., Niederberger, E., Schmidt, R., Kunz, S., Gühring, H., Ritzeler, O., Michaelis, M., & Geißlinger, G. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3118-03.2004 · Cited by 165
Self-citationThe therapeutic potential of NO‐NSAIDs
Wallace, J. L., & Soldato, P. D. (2003) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00125.x · Cited by 162 · cited 1×
“They are able to release NO over prolonged periods of time and have shown reduced gastrointestinal and cardiorenal toxicit”
BackgroundChemokines in joint disease: the key to inflammation?
Haringman, J. J., Ludikhuize, J., & Tak, P. P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.020529 · Cited by 157
Osteoarthritis: symptoms, signs and source of pain
Kean, W. F., Kean, R., & Buchanan, W. W. (2004) · Inflammopharmacology · doi:10.1163/156856004773121347 · Cited by 155 · cited 1×
“This leads to impaired performance in the workplace, and 25% of patients cannot perform their main activities of daily life, which often leads to social isolation and depressio”
BackgroundSharif, M., Kirwan, J., Elson, C. J., Granell, R., & Clarke, S. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20365 · Cited by 153 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=1311">COMP”
International variation in hip replacement rates
Merx, H., Dreinhoefer, K. E., Schräder, P., Stürmer, T., Puhl, W., Günther, K.-P., & Brenner, H. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.3.222 · Cited by 150 · cited 1×
“The situation is even worse in the United States, where a total of ∼500,000 joint replacements are performed per annu”
BackgroundSignaling transduction: target in osteoarthritis
Berenbaum, F. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000133663.37352.4a · Cited by 149
Bordji, K., Grillasca, J., Gouze, J.-N., Magdalou, J., Schohn, H., Keller, J., Bianchi, A., Dauça, M., Netter, P., & Terlain, B. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.16.12243 · Cited by 146
JOBIN, MORTEAU, Han, & Sartor, R. B. (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00646.x · Cited by 145 · cited 1×
“and by overexpression of a dominant-negative inhibitor of NF-κB (IκB) mutan”
BackgroundIntra-articular corticosteroid treatment in osteoarthritis
Creamer, P. (1999) · Current Opinion in Rheumatology · doi:10.1097/00002281-199909000-00016 · Cited by 144
Exercise for knee osteoarthritis
Baker, K., & McAlindon, T. E. (2000) · Current Opinion in Rheumatology · doi:10.1097/00002281-200009000-00020 · Cited by 143
Zhang, X., Mao, Z., & Yu, C. (2004) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2003.12.007 · Cited by 143 · cited 1×
“, and also by gene transfer of a biological IL-1β receptor antagonis”
BackgroundNeuromuscular quadriceps dysfunction prior to osteoarthritis of the knee
Becker, R., Berth, A., Nehring, M., & Awiszus, F. (2004) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2003.11.004 · Cited by 137 · cited 1×
“Patients who had undergone meniscus resection were found to have bilateral quadriceps weaknes”
BackgroundPain and hyperalgesia after intradermal injection of bradykinin in humans
Manning, D. C., Raja, S. N., Meyer, R. A., & Campbell, J. N. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.212 · Cited by 134
Lee, C., Straus, W. L., Balshaw, R. F., Barlas, S., Vogel, S., & Schnitzer, T. J. (2004) · Arthritis Care & Research · doi:10.1002/art.20698 · Cited by 127 · cited 1×
“Recent meta-analyses of available clinical studies, however, reveal that acetaminophen is less effective than NSAIDs and COX2 inhibitor”
BackgroundBone and Fat: Old Questions, New Insights
Gimble, J. M., & NUTTALL, M. E. (2004) · Endocrine · doi:10.1385/endo:23:2-3:183 · Cited by 126 · cited 1×
“If leptin was to stimulate osteophytes through TGFβ production, then increased leptin levels in obesity could represent the link between adipocytes and changes in the join”
BackgroundNF-κB Regulation by IκB Kinase in Primary Fibroblast-Like Synoviocytes
Aupperle, K. R., Bennett, B. L., Boyle, D. L., Tak, P. P., Manning, A. M., & Firestein, G. S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.427 · Cited by 120
Injections in the treatment of osteoarthritis
Ayral, X. (2001) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2001.0177 · Cited by 119 · cited 1×
“They achieve maximum efficacy within less than 1 week, and their benefit lasts for 2–4 week”
BackgroundDistribution of Neuropeptides in Synovium of the Knee With Osteoarthritis
Saito, T., & Koshino, T. (2000) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200007000-00024 · Cited by 114 · cited 1×
“Many sensory nerve fibres that innervate the synovium contain neuropeptides, such as substance P and calcitonin gene-related peptid”
BackgroundINVERSE RELATIONSHIP OSTEOARTHRITIS—OSTEOPOROSIS: WHAT IS THE EVIDENCE? WHAT ARE THE CONSEQUENCES?
Dequeker, J., Boonen, S., Aerssens, J., & Westhovens, R. (1996) · Lara D. Veeken · doi:10.1093/rheumatology/35.9.813 · Cited by 111
Lubberts, E., Joosten, L. A. B., van de Loo, F. A. J., van den Bersselaar, L. A. M., & van den Berg, W. B. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200006)43:6<1397::aid-anr25>3.0.co;2-6 · Cited by 102
NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes.
Aupperle, K. R., Bennett, B. L., Boyle, D. L., Tak, P. P., Manning, A. M., & Firestein, G. S. (1999) · PubMed · Cited by 99
Vascular mechanisms in osteoarthritis
Ghosh, P. B., & Cheras, P. A. (2001) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2001.0188 · Cited by 98 · cited 1×
“Another source of osteoarthritic pain is the vascularization of areas of osteoarthritic bone remodelling, because invading blood vessels are accompanied by sensory nerve fibres, but this hypothesis awaits further clarificatio”
BackgroundThe role of bone in the treatment of osteoarthritis
Lajeunesse, D. (2003) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2003.09.013 · Cited by 97 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=3479">IGF1 ) and bone morphogenetic proteins (BMPs) are endogenous anabolic factors that stimulate cartilage generation and remodellin”
BackgroundPoole, A. R. (2003) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(03)00056-5 · Cited by 91 · cited 1×
“The presence of synovitis is considered to be reflected by elevated levels of hyaluronan in seru”
BackgroundMatsumoto, T., Gargosky, S. E., Iwasaki, K., & Rosenfeld, R. G. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550744 · Cited by 85 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=3479">IGF1 ) and bone morphogenetic proteins (BMPs) are endogenous anabolic factors that stimulate cartilage generation and remodellin”
BackgroundMapp, P. I. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.5.398 · Cited by 76 · cited 1×
“The synovium is densely innervated by small-diameter sensory nerve fibre”
BackgroundInflammation in osteoarthritis.
Abramson, S. B. (2004) · PubMed · Cited by 75
Fan, Z., Chubinskaya, S., Rueger, D. C., Bau, B., Haag, J., & Aigner, T. G. (2004) · PubMed · Cited by 74
Mechanical sensitization of cutaneous C-fiber nociceptors by prostaglandin E2 in the rat
Chen, X., Tanner, K. D., & Levine, J. D. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00345-6 · Cited by 72 · cited 1×
“Moreover, cytokines enhance the release of PGE 2 and histamine from chondrocytes and mast cells, which in turn can (indirectly) increase the sensitization of nociceptor”
BackgroundFuchs, S., Skwara, A., Bloch, M., & Dankbar, B. (2004) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2004.02.005 · Cited by 69 · cited 1×
“They are differentially induced in human osteoarthritic tissue and human synovial fibroblast”
BackgroundFahmi, H., Pelletier, J.-P., Mineau, F., & Pelletier, J. (2002) · Osteoarthritis and Cartilage · doi:10.1053/joca.2002.0835 · Cited by 68 · cited 1×
“IL-1β and tumour-necrosis factor-α (TNFα) induce overexpression of COX2 and PGE 2 in the join”
BackgroundGrowth Factor Expression in the Osteophytes of the Human Femoral Head in Osteoarthritis
Uchino, M., Izumi, T., Tominaga, T., Wakita, R., Minehara, H., Sekiguchi, M., & Itoman, M. (2000) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200008000-00017 · Cited by 68 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=2247">bFGF ), which are highly expressed in osteophytes of the femoral head in OA patient”
BackgroundMenkes, C.-J., & Lane, N. E. (2003) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2003.09.003 · Cited by 67 · cited 1×
“The bony outgrowths at the margins of the joint are referred to as osteophytes or, more precisely, osteochondrophyte”
BackgroundMyers, S. L., Brandt, K. D., Burr, D. B., O’Connor, B. L., & Albrecht, M. E. (1999) · PubMed · Cited by 67
MAST CELLS IN THE SYNOVIUM AND SYNOVIAL FLUID IN OSTEOARTHRHIS
Dean, G. A., Hoyland, J. A., Denton, J., Donn, R. P., & Freemont, A. J. (1993) · Rheumatology · doi:10.1093/rheumatology/32.8.671 · Cited by 64 · cited 1×
“Synovial mast cells are particularly involved and increase in number in O”
BackgroundGlucosamine for osteoarthritis: magic, hype, or confusion?
Chard, J., & Dieppe, P. A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1439 · Cited by 63
Angiogenesis in osteoarthritis and spondylosis: successful repair with undesirable outcomes
Walsh, D. A. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000133662.60223.ee · Cited by 61 · cited 1×
“In addition, endochondral ossification occurs alongside angiogenesi”
Safety of anti-inflammatory treatment--new ways of thinking
Brune, K. (2004) · British journal of rheumatology · doi:10.1093/rheumatology/keh104 · Cited by 61 · cited 1×
“NSAIDs and COX2 inhibitors reduce the levels of prostaglandins, but their use can cause arachidonic acid to be processed through the 5-lipoxygenase (5-LO) pathway, which leads to increased production of pro-inflammatory and gastrotoxic leukotriene”
BackgroundIntra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying
Gossec, L., & Dougados, M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013771 · Cited by 56 · cited 1×
“They achieve maximum efficacy within less than 1 week, and their benefit lasts for 2–4 week”
BackgroundLoeser, R. F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11315 · Cited by 55 · cited 1×
“If leptin was to stimulate osteophytes through TGFβ production, then increased leptin levels in obesity could represent the link between adipocytes and changes in the join”
BackgroundFrançois, M., Richette, P., Tsagris, L., Raymondjean, M., Fulchignoni‐Lataud, M., Forest, C. D., Savouret, J., & Corvol, M. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312708200 · Cited by 54 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=5468">PPARγ ), a member of the nuclear hormone receptor superfamily of ligand-dependent transcription factors, can exert anti-IL-1β effects and downregulates MMP”
BackgroundBone Pain and Pressure in Osteoarthritic Joints
Simkin, P. A. (2004) · Novartis Foundation symposium · doi:10.1002/0470867639.ch12 · Cited by 52
van Osch, G. J. V. M., van der Kraan, P. M., van Valburg, A. A., & van den Berg, W. B. (1996) · Rheumatology International · doi:10.1007/bf01409983 · Cited by 40 · cited 1×
“However, preclinical and clinical studies suggest that cartilage destruction positively correlates with the degree of osteophyte formatio”
BackgroundHereditary disorders mimicking and/or causing premature osteoarthritis
Bálint, G., & Szebenyi, B. (2000) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2000.0063 · Cited by 38 · cited 1×
“cgi?id=277900">Wilson's disease ), can trigger a predisposition to O”
BackgroundExpression and Regulation of Inducible IκB Kinase (IKK-i) in Human Fibroblast-like Synoviocytes
Aupperle, K. R., Yamanishi, Y., Bennett, B. L., Mercurio, F., Boyle, D. L., & Firestein, G. S. (2001) · Cellular Immunology · doi:10.1006/cimm.2002.1885 · Cited by 37 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=4790">NF-κB ) pathway in synovial fibroblast”
Doschak, M. R., Wohl, G. R., Hanley, D. A., Bray, R. C., & Zernicke, R. F. (2004) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2003.12.018 · Cited by 36 · cited 1×
“Although alendronate and risedronate showed some evidence of joint protection in experimental OA in rats and rabbit”
BackgroundOsteophytes in osteoarthritis. Clinical aspects
Brandt, K. D. (1999) · Osteoarthritis and Cartilage · doi:10.1053/joca.1998.0187 · Cited by 34 · cited 1×
“Research is still under way to establish whether these structures are good or bad for the join”
BackgroundStructure-modifying agents for osteoarthritis: an update
Richette, P., & Bardin, T. (2004) · Joint Bone Spine · doi:10.1016/s1297-319x(03)00129-5 · Cited by 32 · cited 1×
“To date, no drugs are available that have shown a significant structure-modifying effect in state-of-the-art placebo-controlled, randomized clinical studie”
BackgroundCalcium crystal–induced inflammation
Halverson, P. B., & Derfus, B. A. (2001) · Current Opinion in Rheumatology · doi:10.1097/00002281-200105000-00013 · Cited by 30
A historic issue of the Annals: three papers examine paracetamol in osteoarthritis
Neame, R., Zhang, W., & Doherty, M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.020727 · Cited by 30 · cited 1×
“Recent meta-analyses of available clinical studies, however, reveal that acetaminophen is less effective than NSAIDs and COX2 inhibitor”
BackgroundNeoantigens in osteoarthritic cartilage
Kato, T., Xiang, Y., Nakamura, H., & Nishioka, K. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000133661.52599.bf · Cited by 28 · cited 1×
“In addition, sporadic reports show the existence of auto-antibodies in synovium of some OA patients, indicating that these contribute to mild chronic synovial inflammatio”
BackgroundNeurogenic acceleration of osteoarthritis
Vilensky, J. A., & Cook, J. (1998) · Current Opinion in Rheumatology · doi:10.1097/00002281-199805000-00016 · Cited by 27 · cited 1×
“This so-called neurogenic inflammation might contribute to localized inflammation in synoviu”
BackgroundFunctional genomics of osteoarthritis
Aigner, T. G., Bartnik, E., Zien, A., & Zimmer, R. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.5.635 · Cited by 26 · cited 1×
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=3553">IL-1β ), growth factors and free radicals, among other”
BackgroundRationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis
Pelletier, J. (2003) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2003.09.014 · Cited by 26 · cited 1×
“Nevertheless, the likelihood of identifying a disease-modifying drug is now greater than ever because the pathophysiological jigsaw is becoming more and more complet”
BackgroundWhittle, B. J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.003 · Cited by 23 · cited 1×
“It has been assumed that NO exerts local protective actions, including mucosal vasodilatatio”
Background(2004) · Novartis Foundation symposium · doi:10.1002/0470867639 · Cited by 19
The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives
Henrotin, Y. E., Sanchez, C., & Reginster, J. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.1.29 · Cited by 17 · cited 1×
“So far, these compounds have failed in the early clinical phase, mainly because of intolerably painful musculo-skeletal side effects, such as tendonitis, which seem to be caused by the relatively broad-spectrum MMP inhibition of these compound”
BackgroundNatural history of nociceptor sensitization: the search for a peripheral mechanism of hyperalgesia
Mizumura, K. (1998) · Pain Reviews · doi:10.1191/096813098678013353 · Cited by 16
Glucosamine for osteoarthritis: part I, review of the clinical evidence.
Biggee, B. A., & McAlindon, T. E. (2004) · PubMed · Cited by 14
Characteristics of COX2 inhibitors questioned
Petit-Zeman, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1517 · Cited by 11
Peripheral and central nervous system mechanisms of joint protection.
O’Connor, B. L., & Vilensky, J. A. (2003) · PubMed · Cited by 10
The use of glucosamine therapy in osteoarthritis
Zerkak, D., & Dougados, M. (2004) · Current Pain and Headache Reports · doi:10.1007/s11916-004-0074-0 · Cited by 10
Lark, M. W. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.04.002 · Cited by 2 · cited 1×
“This pattern of joint involvement points to the hypothesis that joint damage might be caused by a multitude of systemic factors, including metabolic triggers such as lepti”
Background
Research works printed but not linked: 6
- Harris, E. D. Jr. The Bone and Joint decade: a catalyst for progress. Arthritis Rheum 44, 1969–1970 (2004). · doi:10.1002/1529-0131(200109)44:9<1969::aid-art342>3.0.co;2-a
- Brandt, K. D., Smith, G. N. Jr & Simon, L. S. Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum. 43, 1192–1203 (2000). · doi:10.1002/1529-0131(200006)43:6<1192::aid-anr2>3.0.co;2-l
- Bingham, C. et al. Clinically significant placebo improvement occurs by 6 months and is maintained through 24 months in a study of knee OA pain and function. Osteoarthr. Cartil. 12, S132 Abs. P323 (2004).
- Flechtenmacher, J. et al. Bradykinin-receptor-inhibition — a therapeutic option in osteoarthritis? Osteoarthr. Cartil. 12, S137 Abs. P332 (2004).
- Ding, C & Cicuttini, F. Licofelone (Merckle). IDrugs 6, 802–808 (2003).
- Schnitzer, T. J., Kivitz, A. J., Lipetz, S., Sanders, N. & Hee, A. A Phase II study of the efficacy and safety of AZD3582, a CINOD, in subjects with osteoarthritis of the knee. Eur. League Against Rheumatism 2004 Conference Abs OP0016 [online], < http://mcic3.textor.com/cgi-bin/mc/printabs.pl?APP=eular2004SCIE-abstract&TEMPLATE=&keyf=0094&showHide=show&client= > (2004)
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
“In one mouse model, injection of UBX0101 selectively eliminated senescent cells and reduced proteoglycan loss, which alleviated the cartilage degradation and pain caused by OA.339 Fenofibrate, a PPARα agonist, clears SAβ-gal-positive chondrocytes by promoting apoptosis.595 Fisetin, a flavonoid drug, alleviates inflamm…”
BackgroundInfluentialJeon, O. H., Kim, C., Laberge, R.-M., Demaria, M., Rathod, S., Vasserot, A. P., Chung, J. W., Kim, D. H., Poon, Y., David, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4324 · Cited by 1,515
Senescent cells: an emerging target for diseases of ageing
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.116 · Cited by 1,284
Proteases involved in cartilage matrix degradation in osteoarthritis
Troeberg, L., & Nagase, H. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.06.020 · Cited by 579
Tang, S., Zhang, C., Oo, W. M., Fu, K., Risberg, M. A., Bierma-Zeinstra, S. M., Neogi, T., Atukorala, I., Malfait, A.-M., Ding, C., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00594-6 · Cited by 476
“Once regarded as a simple ‘wear and tear’ or ‘degenerative’ joint disease, OA is now understood as a complex, multifactorial disorder affecting the entire joint, including the bone, cartilage, ligaments and muscles 2,3 (Fig.”
Metadata
- Authors
- Wieland, H. A., Michaelis, M., Kirschbaum, B. J., & Rudolphi, K. A.
- Affiliations
- Sanofi (Germany) (DE)
- Corresponding author
- Wieland, Heike A.
- ORCID
- Michaelis, Martin
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-04
- Volume
- 4
- Issue
- 4
- Pages
- 331-344
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1487036716
- Cited by
- 585
- References
- 124
- Citations by year
- 2026: 34 · 2025: 32 · 2024: 44 · 2023: 31 · 2022: 36 · 2021: 34 · 2020: 25 · 2019: 36 · 2018: 24 · 2017: 31 · 2016: 26 · 2015: 29 · 2014: 29 · 2013: 32 · 2012: 29
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacological Effects of Medicinal Plants
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Keywords
- osteoarthritis, disease-modifying therapy, early-onset osteoarthritis, pharmacotherapy, treatment options
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Humans, Osteoarthritis, Pain, Drug Design, Molecular Structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.